The Video Journal of Hematology & Hematological Oncology The European Hematology Association (EHA) Congress in Madrid, Spain. Firas El Chaer, MD, University of Virginia, Charlottesville, VA, discusses a study investigating the predictive value of measurable residual disease (MRD) testing by multiparameter flow cytometry (MFC) for patients with acute myeloid leukemia (AML) in the first complete remission (CR1).